At the news
? NEUTRALIMPACT 2/10 CLUSTER filed May 7, 2026 at 16:31 ET
Three top executives at United Therapeutics (CEO, CFO, General Counsel) executed option exercises and sold a portion of the resulting shares in the week following the company's Q1 2026 earnings release. Total open-market sales were $1.44M, or ~0.006% of the $24.2B market cap, a trivial amount relative to company size. The sales appear to be routine tax- and cash-management transactions tied to option exercises, not a signal of deteriorating fundamentals.
- Total open-market sales by 3 insiders: $1.44M (0.006% of market cap)
- CEO Martine Rothblatt sold 2,871 shares for $1.63M across 4 trades, but also exercised options on 38,000 shares (mostly non-cash)
- CFO James Edgemond sold 1,849 shares for $1.05M, while exercising options on 20,000 shares
- EVP Paul Mahon sold 80 shares for $46.6K, exercising options on 8,300 shares
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access